Key Takeaway: Precision BioSciences has finalized a licensing agreement with TG Therapeutics for its cell therapy, Azer-Cel, aimed at treating autoimmune diseases. The deal includes an upfront payment of $17.5 million and potential milestone payments totaling up to $288 million. This financial influx is expected to extend Precision's cash runway into the first half of 2026, supporting its ongoing projects.
Price reaction · baseline $11.94 (2024-01-08 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
+10.1%
day 1
+7.4%
day 3
+8.1%
Market Sentiment Analysis
POSITIVE FACTORS
Precision BioSciences secures a significant upfront payment.
Potential for substantial milestone payments enhances financial outlook.
The deal extends Precision's cash runway into 2026.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Precision to Receive $17.5 Million in Upfront and Near-Term Payments with Potential for up to $288 Million in Other Development Milestone Payments – Upfront Cash and Near-Term Payments Expected to Extend Precision’s Cash Runway into the First Half of 2026 and Fund Precision’s Wholly-Owned In Vivo
Frequently Asked Questions
What is the value of the licensing deal?
The licensing deal is valued at $17.5 million upfront, with potential for up to $288 million in milestone payments.
What will the deal fund for Precision BioSciences?
The deal is expected to extend Precision's cash runway into the first half of 2026.
What is Azer-Cel used for?
Azer-Cel is a cell therapy aimed at treating autoimmune diseases.